Printer Friendly

BURROUGHS WELLCOME VOLUNTARILY REDUCES PRESCRIPTION DRUG PRICES TO FEDERALLY FUNDED PUBLIC HEALTH CLINICS AND GOVERNMENT AGENCIES USING FSS

 BURROUGHS WELLCOME VOLUNTARILY REDUCES PRESCRIPTION DRUG PRICES TO FEDERALLY FUNDED PUBLIC HEALTH CLINICS AND GOVERNMENT AGENCIES USING FSS
 RESEARCH TRIANGLE PARK, N.C., Feb. 12 /PRNewswire/ -- Burroughs Wellcome Co. today announced that it will voluntarily reduce prices for its prescription medicines to certain Federally funded public health clinics, effective March 1. The company is taking this step to demonstrate its support of Senate Bill S1729, sponsored by Senators Edward Kennedy (D) of Massachusetts and Orrin Hatch (R) of Utah.
 Burroughs Wellcome Co. will provide discounts comparable to those provided to States through the Federal Medicaid Rebate contract on its prescription product line to certain qualified Federally funded health centers. The qualified clinics and centers, as described in S1729, include AIDS clinics, sexually transmitted disease clinics, community and migrant health centers, homeless programs, public housing clinics and mental health, tuberculosis and family planning clinics.
 It is important to note that this program covers all Burroughs Wellcome prescription products including the AIDS medication Retrovir(R) brand zidovudine (AZT) and the herpesvirus therapy Zovirax(R) brand acyclovir. The discounts will be effective March 1, and the company is working on a mechanism to implement the reductions.
 In addition, Burroughs Wellcome will roll back the prices extended to all Federal agencies utilizing the Federal Supply Schedule (FSS) to the Sept. 1, 1990 price level for products listed in the schedule as of that date. Agencies using this schedule include the Veterans Administration, U.S. Military and U.S. Public Health Service. Products that have been added to the Federal Supply Schedule since Sept. 1, 1990 will have their prices rolled back to their introductory price at the time they were added to the FSS.
 These two actions will increase the total rebates and discounts provided to Federal and State agencies and programs by Burroughs Wellcome to an estimated $25 million in 1992 and more than $40 million in 1993.
 "This new pricing policy has been undertaken to help the Federal government in its efforts to provide services to the estimated 6 millionope thi move will have a beneficial impact on the passage of this important legislation and will help government agencies address the health care issues which affect us all."
 Tracy noted that Burroughs Wellcome expanded its patient assistance program for people infected with the human immunodeficiency virus (HIV) last fall. This program, one of the largest patient assistance programs for HIV disease established to date, will provide as much as $10 million a year in free medicines to people with HIV infection.
 The program, which began in 1987 as a program that provided free Retrovir brand zidovudine (AZT) to needy patients, now includes all Burroughs Wellcome prescription medicines used in the treatment of HIV and its associated opportunistic infections. The HIV Patient Assistance Program is a component of a broader, long-standing company patient assistance program that provides all Burroughs Wellcome prescription products to financially disadvantaged individuals.
 Burroughs Wellcome Co. is a research-based pharmaceutical company headquartered in Research Triangle Park, N.C. The company researches, develops, manufactures and markets a wide range of prescription medications. Burroughs Wellcome Co. is a wholly owned subsidiary of The Wellcome Foundation Ltd. (Wellcome plc) of London, an international pharmaceutical company with a 110 year heritage of commitment to the improvement of human health through medicines for poorly understood or inadequately treated diseases.
 -0- 2/12/92
 /CONTACT: Kathy S. Bartlett, 919-248-4302, or Sharon Bickus, 919-248-8611, both of Burroughs Wellcome Co./ CO: Burroughs Wellcome Co. ST: North Carolina IN: MTC SU:


JZ-CM -- CH002 -- 9272 02/12/92 13:07 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 12, 1992
Words:591
Previous Article:ALWAYS TECHNOLOGY APPOINTS CONTROLLER, TECHNICAL SUPPORT SPECIALIST
Next Article:UNION CARBIDE REPORTS AUDITED 1991 RESULTS; NO CHANGE FROM PRELIMINARY RESULTS ANNOUNCED ON JAN. 27
Topics:


Related Articles
ZOVIRAX(R) BENEFITS HEALTHY CHILDREN WITH CHICKENPOX
BRISTOL-MYERS SQUIBB ANNOUNCES VOLUNTARY REDUCTION IN PHARMACEUTICAL PRICES TO FEDERAL GOVERNMENT
BRISTOL-MYERS SQUIBB ANNOUNCES VOLUNTARY REDUCTION IN PHARMACEUTICAL PRICES TO FEDERAL GOVERNMENT
SYNTEX EXTENDS DISCOUNTED PRICES TO FEDERALLY FUNDED PUBLIC HEALTH SERVICE CENTERS
SEARLE ANNOUNCES SPECIFICS OF DISCOUNT PRICING TO PUBLIC HEALTH SERVICE CLINICS
PFIZER ANNOUNCES SUPPORT FOR KENNEDY/HATCH BILL THAT WOULD PROVIDE DRUG DISCOUNTS TO PUBLIC HEALTH CLINICS
SANDOZ ANNOUNCES PRICE REDUCTION TO VETERANS ADMINISTRATION, PUBLIC HEALTH SERVICE AND OTHER FEDERAL CLINICS
BURROUGHS WELLCOME CO. AND WYETH-AYERST TO CO-PROMOTE NEW TREATMENT FOR CHICKENPOX
BURROUGHS WELLCOME CO. SUPPORTS HURRICANE RELIEF EFFORT
BURROUGHS WELLCOME SUES NOVOPHARM FOR PATENT INFRINGEMENT

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters